What Respicardia does

Respicardia, operating as ZOLL Respicardia, Inc., is a Minnetonka, Minnesota-based medical device subsidiary of ZOLL Medical Corporation that develops and commercializes the remedē® System — an implantable Transvenous Phrenic Nerve Stimulation (TPNS) device for treating moderate to severe central sleep apnea (CSA) in adults. The product family (remedē, remedē EL, and remedē EL-X) functions as a diaphragm pacemaker: the implanted device automatically detects apneic events during sleep and stimulates the phrenic nerve to restore normal breathing, distinguishing it from mask-based CPAP therapy. The remedē System is the first FDA-approved non-mask therapy for moderate to severe CSA and has CE Mark approval for the model 1001, with Transvenous Phrenic Nerve Stimulation recommended as a treatment option in the 2025 AASM CSA clinical guidelines.

The company generates revenue primarily through Class III implantable hardware sales to hospitals, supplemented by clinical support, device programming, and follow-up services. Go-to-market follows a traditional medical device enterprise field-sales model targeting hospital-based electrophysiologists, cardiologists, and sleep specialists, with patient demand supported by a 'Find a Doctor' referral tool and patient screener on the remedē website. Respicardia sells to U.S. hospitals broadly, has expanded into selected European markets via CE Mark, and is broadening from academic medical centers into community health systems — Novant Health Forsyth Medical Center becoming the first non-academic U.S. center to offer the therapy. The company was founded in 2006, operates with 11–50 employees, and has raised approximately USD 160M across nine funding rounds (2006–2017) prior to operating as a wholly-owned ZOLL subsidiary.

Name

Respicardia

Legal name

ZOLL Respicardia, Inc.

Website

https://respicardia.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Short description

Respicardia, a ZOLL Medical subsidiary, develops the remedē® System, an FDA-approved implantable phrenic nerve stimulator that treats moderate to severe central sleep apnea in adults, sold to hospitals through electrophysiologists, cardiologists, and sleep specialists.

Ownership category

akta.pro rank

Product category

Implantable Sleep Apnea Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Sleep Apnea Therapy Devices (CPAP/APAP/BiPAP/ASV) (HLAHAGAA)

Keywords

• Implantable medical devices
• Sleep apnea treatment
• Phrenic nerve stimulation
• Central sleep apnea therapy
• Cardiac implantable devices

Headquarters

HQ city

Minnetonka

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Implantable Medical Device Sales: Respicardia generates revenue through the sale of its remedē System implantable devices to hospitals and healthcare providers. The device is implanted surgically, generating one-time revenue per procedure along with associated follow-up services, device maintenance, and periodic adjustments.
2. Clinical Support and Follow-up Services: Ongoing clinical support, device programming adjustments, and patient monitoring services associated with the implanted remedē System, creating a recurring service relationship with implanting healthcare providers.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Respicardia develops and sells the remedē® System, an FDA-approved implantable phrenic nerve stimulator that treats moderate to severe central sleep apnea (CSA) in adult patients. The device uses Transvenous Phrenic Nerve Stimulation (TPNS) to automatically detect breathing pauses during sleep and signal the diaphragm to restore normal breathing, serving as the first non-mask therapy for CSA. The company operates as a division of ZOLL Medical Corporation and sells its Class III implantable devices to hospitals and implanting physicians.

Product overview

Respicardia (now a division of ZOLL Medical Corporation) offers the remedē® System family of products—consisting of the remedē® System, remedē® EL System, and remedē® EL-X System—as implantable medical devices for treating central sleep apnea. The remedē® System was the first FDA-approved non-mask therapy for moderate to severe CSA in adults. These devices function as diaphragm pacemakers using transvenous phrenic nerve stimulation (TPNS) to automatically restore normal breathing patterns during sleep.

Differentiator

Problem solved

Functional benefit

Brands

• rem.edē System: FDA-approved implantable phrenic nerve stimulator for treating moderate to severe central sleep apnea in adults
• rem.edē EL System
• rem.edē EL-X System

Products and services

• remedē® System

Named customers2 records

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• American Academy of Sleep Medicine (AASM)coreStrategic or Co-development PartnerTransvenous Phrenic Nerve Stimulation (TPNS), the technology underlying the remedē System, was recommended as a treatment option in the 2025 AASM CSA guidelines. This guideline inclusion positions TPNS as a clinically validated standard-of-care option and represents a deep strategic endorsement from the leading sleep medicine professional body.
• ZOLL Medical CorporationcoreOthersRespicardia operates as a division and subsidiary of ZOLL Medical Corporation, headquartered in Minnetonka, MN. The remedē System is marketed under the ZOLL Respicardia brand. ZOLL provides corporate infrastructure, distribution scale, and cross-selling opportunities within its broader medical device portfolio.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Inspire Medical Systems: Inspire Medical Systems develops the Inspire UAS System, an implantable neurostimulator (hypoglossal nerve stimulation) for obstructive sleep apnea. It is the most direct comparable to Respicardia as a publicly-traded implantable neurostimulator targeting sleep-disordered breathing with a similar hospital-based, specialist-implanted commercial model.

Emerging players

• Nyxoah: Nyxoah is developing the Genio system, a bilateral hypoglossal nerve stimulator for OSA. It is an emerging neurostimulation peer in the sleep apnea implant space, competing for similar implanting physician specialists and hospital accounts as Respicardia.
• Apnimed: Apnimed is developing pharmaceutical (pill-based) therapies for obstructive and central sleep apnea. While non-device, it represents an emerging alternative treatment pathway that competes with Respicardia for the same CSA patient population.
• Axonics: Axonics develops implantable sacral neuromodulation devices for incontinence and overactive bladder. It is an emerging peer in Class III implantable neurostimulators with similar regulatory, manufacturing, and hospital sales dynamics to Respicardia.

Broad incumbents

• ResMed: ResMed is the global market leader in CPAP and sleep-disordered-breathing masks and devices. It competes broadly with Respicardia for sleep apnea patients, particularly as first-line CPAP therapy, and could expand into CSA-specific or implantable offerings over time.
• Koninklijke Philips (Philips Respironics): Philips Respironics is a major incumbent in sleep apnea and respiratory care, with a broad CPAP and ventilation portfolio. It is the primary alternative to ResMed for first-line CSA treatment and a potential competitor should it move into implantable CSA therapy.
• LivaNova: LivaNova is a neuromodulation and cardiac surgery company that acquired ImThera Medical, a phrenic nerve stimulation developer for sleep apnea. LivaNova is a broad incumbent peer with direct overlap to Respicardia's phrenic nerve stimulation technology platform.
• Medtronic: Medtronic is the global leader in implantable neurostimulators (spinal cord, deep brain, sacral) and cardiovascular devices. Its broader neuromodulation and cardiac rhythm management franchises provide comparable technology platforms, and it could enter the CSA neurostimulation market.
• Fisher & Paykel Healthcare: Fisher & Paykel Healthcare is a leading respiratory care and sleep apnea equipment manufacturer. It competes with Respicardia indirectly as a CPAP and nasal interface provider and is a relevant comparable for hospital-based respiratory care sales models.

Others

• ZOLL Medical Corporation (Asahi Kasei): ZOLL Medical, Respicardia's parent company and a subsidiary of Asahi Kasei, manufactures defibrillators, cardiac resuscitation devices, and respiratory care equipment. It is the corporate parent enabling Respicardia's commercialization infrastructure and is relevant for understanding Respicardia's go-to-market leverage.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/remedesystem
• YouTubeyoutube.com/@remedesystem
• Facebookfacebook.com/remedesystem
• LinkedInlinkedin.com/company/respicardia-inc-

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds9 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Respicardia